acetylhydrolase-in-1

Acetylhydrolase-IN-1 is an inhibitor of the esterase 1-Alkyl-2-acetylglycerophosphocholine (Alkylacetyl-GPC: acetylhydrolase).

Lp-PLA2-IN-10 是一种有效的脂蛋白相关磷脂酶 A2 (Lp-PLA2) 抑制剂。Lp-PLA2-IN-10 能够用于神经退行性相关疾病的研究，如阿尔茨海默病(AD)、青光眼、年龄相关的黄斑变性 (AMD)，或者包括动脉粥样硬化等心血管疾病。Lp-PLA2 曾经被称作血小板活化因子乙酰水解酶 (PAF-AH)，是一种参与脂蛋白脂质或磷脂水解的磷脂酶 A2。

Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (10 mg kg) decreases serum cholesterol levels and total bod......